H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Novavax (NVAX – Research Report) today and set a price target of $35.00. The company’s shares closed yesterday at $7.12.
According to TipRanks, Bernardino is a 4-star analyst with an average return of 9.9% and a 27.25% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Cassava Sciences, Citius Pharmaceuticals, and Novavax.
Currently, the analyst consensus on Novavax is a Moderate Buy with an average price target of $25.00, which is a 251.12% upside from current levels. In a report released yesterday, B.Riley Financial also maintained a Buy rating on the stock with a $15.00 price target.
See the top stocks recommended by analysts >>
Based on Novavax’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $424.43 million and a net profit of $58.01 million. In comparison, last year the company earned a revenue of $185.93 million and had a GAAP net loss of $510.49 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Novavax, Inc. is a late-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. Its vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
Read More on NVAX:
